PSMA-PET Imaging in Patients With Metastatic Prostate Cancer: Institutional Evaluation of Detection Yield Performance and Reproducibility

NACompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

October 2, 2017

Primary Completion Date

April 30, 2018

Study Completion Date

April 30, 2018

Conditions
Prostate Cancer
Interventions
DIAGNOSTIC_TEST

PSMA -PET/CT scanning

"PET/CT scanning is performed on hybrid PET/CT scanners. Patients should fast for at least 4 hours to facilitate transit of oral contrast into the distal small bowel. An oral contrast product can be administered and \[18F\]-DCFPyL is injected by IV rapid bolus followed by saline flush. 80-100 minutes following \[18F\]-DCFPyL injection, CT and PET images are consecutively acquired from the base of the skull to the upper thighs. An MRI of the questioned lesion sites may be performed.~Uptake of lesions is measured with SUVmax. Hepatic and blood pool SUV is determined for the computation of tumor-to-liver and tumor-to-blood ratios.~15 patients max will undergo a second PSMA-PET scan on the same camera with the same protocol using a different tracer batch within 2 weeks of the initial PSMA-PET evaluation in order to determine test-retest repeatability of the imaging procedure using a Bland-Altman analysis (per lesion analysis)."

Trial Locations (1)

Unknown

Centre Hospitalier de l'Université de Montréal, Montreal

All Listed Sponsors
lead

Centre hospitalier de l'Université de Montréal (CHUM)

OTHER

NCT03486886 - PSMA-PET Imaging in Patients With Metastatic Prostate Cancer: Institutional Evaluation of Detection Yield Performance and Reproducibility | Biotech Hunter | Biotech Hunter